COHORT · very low certainty
Early anatomical rescue after switching to aflibercept 8 mg in faricimab-refractory neovascular AMD
In faricimab-refractory nAMD, switching to aflibercept 8 mg was associated with CST thinning; not yet practice-changing without randomized comparison.
324.6MDcentral subfield thickness at week 8 vs baselineObservational association
Design Cohortn 32Funding Not reported
- Why it matters
- First cohort reporting CST recovery after switching from faricimab; suggests a rescue pathway for refractory nAMD, though observational design limits certainty.
- Prior evidence
- No prior-evidence claim in abstract.
- Limitations
- Small retrospective cohort (n=32); no comparator arm; unadjusted confounders.
Statistics · confidence intervals & p-values
central subfield thickness at week 8 vs baseline: MD 324.6 p<0.05
Source
Chang W. Early anatomical rescue after switching to aflibercept 8 mg in faricimab-refractory neovascular AMD. International ophthalmology. Tuesday, August 25, 2026.
doi:10.1007/s10792-026-04213-5Read original ↗
doi:10.1007/s10792-026-04213-5Read original ↗
Generated, then checked against the source · how this brief was built →
Sign in to rate and bookmark articles
Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.